Skip to main content
SpringerLink
Log in

Rationale of Antibiotics Anti-MRSA in Pneumonia

  • Conference paper
  • First Online:
Anaesthesia, Pharmacology, Intensive Care and Emergency A.P.I.C.E.

  • 1466 Accesses

Abstract

Staphylococcus aureus is a bacterium causing a broad variety of infections, ranging from minor skin infections to severe pneumonia and sepsis. The genetic adaptation occurred after the introduction of meticillin into clinical practice in the 1960s [1] has led to a multidrug-resistant pathogen, meticillin-resistant S. aureus (MRSA). MRSA is characterized by the mecA gene that encodes the penicillin binding protein 2a (PBP2a) that permits growth in the presence of meticillin and tends to have multidrug resistance. MRSA is resistant to b-lactam antibiotics, including penicillin and cephalosporins but not ceftaroline that is able to bind PBP2a.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Daum RS (2007) Skin and soft tissue infections caused by methicillinresistant Staphylococcus aureus. N Engl J Med 357:380–390

    Article  PubMed  CAS  Google Scholar 

  2. Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM (1971) Bacterial pneumonia during the Hong Kong influenza epidemic of 1968–1969. Arch Intern Med 127:1037–1041

    Article  PubMed  CAS  Google Scholar 

  3. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS (2005) Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 128:1414–1422

    Article  PubMed  Google Scholar 

  4. Gillet Y, Issartel B, Vanhems P et al (2002) Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753–759

    Article  PubMed  CAS  Google Scholar 

  5. Kollef MH, Shorr A, Tabak YP, et al (2005) Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128:3854–3862

    Google Scholar 

  6. Rello J, Torres A, Ricart M et al (1994) Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin- sensitive episodes. Am J Respir Crit Care Med 150:1545–1549

    Article  PubMed  CAS  Google Scholar 

  7. Bodi M, Ardanuy C, Rello J (2001) Impact of gram-positive resistance on outcome of nosocomial pneumonia. Crit Care Med 29:N82–N86

    Article  PubMed  CAS  Google Scholar 

  8. Gonzalez C, Rubio M, Romero-Vivas J, et al (1999) Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29:1171–1177

    Google Scholar 

  9. Rello J (2007) Importance of appropriate initial antibiotic therapy and deescalation in the treatment of nosocomial pneumonia. Eur Respir Rev 16:33–39

    Article  Google Scholar 

  10. Shurland S, Zhan M, Bradham DD, Roghmann MC (2007) Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28:273–279

    Article  PubMed  Google Scholar 

  11. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA (2006) Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 26:539–550

    Article  PubMed  CAS  Google Scholar 

  12. Lamer C, de Beco V, Soler P et al (1993) Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281–286

    Article  PubMed  CAS  Google Scholar 

  13. Georges H, Leroy O, Alfandari S et al (1997) Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 16:385–388

    Google Scholar 

  14. Jeffres MN, Isakow W, Doherty JA et al (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care–associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947–955

    Article  PubMed  Google Scholar 

  15. Hidayat LK, Hsu DI, Quist R, et al (2006) Highdose vancomycin therapy for methicillin-resistant Staphylococcusaureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144

    Google Scholar 

  16. Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208–1215

    Article  PubMed  CAS  Google Scholar 

  17. Rybak M, Lomaestro B, Rotschafer JC et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm 66:82–98

    Google Scholar 

  18. Rybak MJ (2006) The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42(1):S35–S39

    Google Scholar 

  19. Conte JE Jr, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46:1475–1480

    Article  PubMed  CAS  Google Scholar 

  20. Rubinstein E, Cammarata S, Oliphant T, Wunderink R (2001) Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32:402–412

    Article  PubMed  CAS  Google Scholar 

  21. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH (2003) Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 25:980–992

    Article  PubMed  CAS  Google Scholar 

  22. Wunderink RG, Rello J, Cammarata SK, et al (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789–1797

    Google Scholar 

  23. Stevens DL, Herr D, Lampiris H, et al (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481–1490

    Google Scholar 

  24. Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin- resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled study. Clin Infect Dis 54:621–629

    Article  PubMed  CAS  Google Scholar 

  25. Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2:289–300

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy

    Francesco Scaglione

Authors
  1. Francesco Scaglione
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Scaglione .

Editor information

Editors and Affiliations

  1. UCO di Anestesia e Rianimazione, University Hospital, Dept. of Anesthesia and Intensive Care, School of Medicine Catania, Catania, Italy

    Antonino Gullo

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this paper

Cite this paper

Scaglione, F. (2014). Rationale of Antibiotics Anti-MRSA in Pneumonia. In: Gullo, A. (eds) Anaesthesia, Pharmacology, Intensive Care and Emergency A.P.I.C.E.. Springer, Milano. https://doi.org/10.1007/978-88-470-5516-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5516-2_12

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5515-5

  • Online ISBN: 978-88-470-5516-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation